Indications for: INJECTAFER
Iron deficiency anemia (IDA) in patients ≥1yr of age who have intolerance or insufficient response to oral iron. In adults who have non-dialysis-dependent chronic kidney disease.
Adults and Children:
<1yr: not established (IDA). Give by slow IV push (undiluted) at rate of approx. 100mg (2mL)/min; or by IV infusion (diluted) over 15mins. When giving via IV infusion, dilute to concentration not less than 2mg/mL of iron. ≥1yr (<50kg): 15mg/kg/dose in 2 doses separated by ≥7 days per course; (≥50kg): 750mg/dose in 2 doses separated by ≥7 days (total cumulative dose per course: 1500mg). For adults (≥50kg): alternatively can give 15mg/kg (up to max 1000mg) as a single-dose. May repeat treatment if IDA reoccurs.
Monitor for hypersensitivity reactions during and after administration for ≥30mins and until clinically stable. Have epinephrine inj immediately available. Possible risk for hypophosphatemia if history of GI disorders associated with malabsorption of fat-soluble vitamins or phosphate, hyperparathyroidism, vitamin D deficiency, malnutrition. Monitor serum phosphate levels in at-risk patients who require a repeat course. Monitor for hypertension after each administration. Avoid extravasation. Neonates. Pregnancy (risk of fetal bradycardia esp. during 2nd & 3rd trimester). Nursing mothers.
Possible risk for hypophosphatemia with concurrent or prior use of drugs that affect proximal renal tubular function. Lab assays may overestimate serum iron and transferrin bound iron within 24hrs after administration.
Nausea, hypertension, flushing, hypophosphatemia, dizziness; rare: hypersensitivity reactions.
Generic Drug Availability:
Single-dose vial (15mL)—1